Heart failure with normal ejection fraction: current diagnostic and management strategies

References

• Walter J Paulus, Carsten Tscho¨pe, John E Sanderson et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur. Heart J. 28(20), 2539–2550 (2007).
   PubMed Web of Science ®Google Scholar
• Fischer M, Baessler A, Hense HW et al. Prevalence of left ventricular diastolic dysfunction in the community. Results from a Doppler echocardiographic-based survey of a population sample. Eur. Heart J. 24(4), 320–328 (2003).
   PubMed Web of Science ®Google Scholar
• Gutwitz JH, Majid DJ, Smith DH et al. Contemporary prevalence and correlate of incident heart failure with preserved Ejection fraction. Am. J. Med. 126(5), 393–400 (2013).
   PubMed Web of Science ®Google Scholar
• Chatterjee K, Massie B. Systolic and diastolic heart failure: Differences and similarities. J. Cardiac. Fail. 13(7), 569–576 (2007).
   Google Scholar
• Redfield MM, Jacobson SJ, Burnett JC et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289(2), 194–202 (2003).
   PubMed Web of Science ®Google Scholar
• Wang J, Kurrelmeyer KM, Torre-Amione N, Nagueh SF. Systolic and diastolic dyssynchrony in patients with diastolic heart failure and the effect of medical therapy. J. Am. Coll. Cardiol. 49(1), 88–96 (2007).
   PubMed Web of Science ®Google Scholar
• Aurigemma GP, Zile MR, Gasch WH. Contractile behavior of the left ventricle in diastolic heart failure. Circulation 113, 296–304 (2006).
   PubMed Web of Science ®Google Scholar
• Konstam MA. ‘Systolic and diastolic dysfunction’ in heart failure? Time for a new paradigm. J. Cardiac. Fail. 9(1), 1–3(2003).
   PubMed Web of Science ®Google Scholar
• Shah PM, Pai RG. Diastolic heart failure. Curr. Probl. Cardiol. 17, 783–845 (1992).
   Web of Science ®Google Scholar
• Michael R. Zile, Dirk L. Brutsaert, New concepts in diastolic dysfunction and diastolic heart failure: part II causal mechanisms and treatment. Circulation 105(12), 1503–1508 (2002).
   PubMed Web of Science ®Google Scholar
• Jae K Oh, James B Steward, Jamil Tajik. Assessment of diastolic function and diastolic heart failure. In: The Echo Manual book (3rd edition). Wolters Kluwer Health publisher, Philadelphia, Baltimore, Newyork, London, Buenos Aires, Hong Kong, Sydney, Tokyo, 120–142 (2007).
   Google Scholar
• Arnold M. Katz, Molecular and cellular basis of contraction. In: Atlas of Heart Failure Book (5th edition). Colucci WS (Ed.). Springer science+Business Media Publisher, 15–27 (2008).
   Google Scholar
• Hunt SA, Abraham WT, Chin MH. 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the american college of cardiology Foundation/American heart association task force on practice guidelines: developed in collaboration with the international society for heart and lung transplantation. Circulation 119, e391–e479 (2009).
   PubMed Web of Science ®Google Scholar
• Cazorla O, Freiburg A, Helmes M et al. Differential expression of cardiac titin isoforms and modulation of cellular stiffness. Circ. Res. 86(1), 59–67 (2000).
   PubMed Web of Science ®Google Scholar
• Jalil JE, Doering CW, Janicki JS et al. Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ. Res. 64(6), 1041–1050 (1989).
   PubMed Web of Science ®Google Scholar
• Ikonomidis JS, Zile MR, Spinale FG. Yarbrough WM, Mukherjee R. Myocardial remodeling with aortic stenosis and after aortic valve replacement: mechanisms and future prognostic implications. J. Thorac. Cardiovasc. Surg. 143(3), 656–664 (2012).
   PubMed Web of Science ®Google Scholar
• Martos R, Baugh J, Ledwidge M et al. Diastolic heart failure; evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 115 (7), 888–895 (2007).
   PubMed Web of Science ®Google Scholar
• Querejeta R, Lopez B, Gonzalez A et al. Increased collagen type 1 synthesis in patients with heart failure of hypertensive origin: Relation to myocardial fibrosis. Circulation 110(10), 1263–1268 (2004).
   PubMed Web of Science ®Google Scholar
• Chaanine AH, Gordon RE, Kohlbrenner E, Benard L, Jeong D, Hajjar RJ. potential role of bnip3 in cardiac remodeling, myocardial stiffness and endoplasmic reticulum-mitochondrial calcium homeostasis in diastolic and systolic heart failure. Circ. Heart Fail. Published online before print (2013).
   PubMed Web of Science ®Google Scholar
• Okuda S, Yano M. The roles of calcium and phosphorus in cardiovascular diseases. excitation-contraction coupling and intracellular calcium cycling in failing hearts (abstract, article itself in Japanese). Clin. Calcium 23(4) 471–480 (2013).
   PubMedGoogle Scholar
• Paganelli WC, Creager MA, Dzau VJ. Cardiac regulation of renal function. In: The Text Book of Cardiology. Cheng TO (Ed.). Pergamon Press, New York, 1010–1020 (1986).
   Google Scholar
• Noharia A, Creager MA. Neurohormonal, renal and vascular adjustments in heart failure. In: Atlas of Heart Failure Book (5th edition). Colucci WS (Ed.). Springer science+Business Media Publisher, 89–116 (2008).
   Google Scholar
• Hirsch AT, Pinto YM, Schunkert H, Dzau VJ. Potential role of renin- angiotensin system in the pathophysiology of congestive heart failure. Am. J. Cardiol. 66, 22D–30D (1990).
   Google Scholar
• Sciarretta S, Paneni F, Palano F et al. Role of the renin-angiotensin-aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction. Clin. Sci. (Lond.) 116(6), 467–477 (2009).
   PubMed Web of Science ®Google Scholar
• Chinnaiyan KM, Alexander D, McCullough PA. Role of angiotensin II in the evolution of diastolic heart failure. J. Clin. Hypertens. (Greenwich) 7(12), 740–747 (2005).
   PubMedGoogle Scholar
• Floras JS. Clinical aspects of sympathetic activation and parasympathetic withdrawal in Heart failure. J. Am. Coll. Cardiol. 22, 72A–84A (1993).
   PubMed Web of Science ®Google Scholar
• Cohn JN, Levine TB, Olivari MT et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. NEJM 311, 819–823 (1984).
   PubMed Web of Science ®Google Scholar
• Kimura K, Kanazawa H, Ieda M et al. Norepinephrine-induced nerve growth factor depletion causes cardiac sympathetic denervation in severe heart failure. Auton. Neurosci. 156(1–2), 27–35 (2010).
   PubMed Web of Science ®Google Scholar
• Diez J, Querejeta R, Lopez B et al. Losartan dependent regression of myocardial fibrosis is associated with reduction in left ventricular chamber stiffness in hypertensive patients. Circulation 105(21), 2512–2517 (2002).
   PubMed Web of Science ®Google Scholar
• Warner JG Jr, Metzger DC, Kitzman DW, Wesley DJ, Little WC. Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise. J. Am. Coll. Cardiol. 33(6), 1567–1572 (1999).
   PubMed Web of Science ®Google Scholar
• Little WC, Zile MR, Klein A, Appleton CP, Kitzman DW, Wesley-Frrington DJ. Effect of Losartan and hydrochlorothiazide on exercise tolerance in exetional hypertension and left ventricular diastolic dysfunction. Am. J. Cardiol. 98(3), 383–388 (2006).
   PubMed Web of Science ®Google Scholar
• Little WC, Wesly-Farrington DJ, Hoyle J et al. Effect of Candesartan and verapamil on exercise tolerance in diastolic dysfunction. J. Cardiovasc. Pharmacol. 43(2), 288–293 (2004).
   PubMed Web of Science ®Google Scholar
• Cleland JG, Tendera AM, Adamus J PEP-CHF investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur. Heart 27, 23338–2345 (2006).
   Web of Science ®Google Scholar
• Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362(9386),777–781 (2003).
   PubMed Web of Science ®Google Scholar
• Massie BM, Carson PE, McMurray JJ et al. Irbesartan in patients with heart failure and preserved ejection fraction. NEJM 359(23), 2456–2467 (2008).
   PubMed Web of Science ®Google Scholar
• Marcus D. Flather, Marcelo C. Shibata. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur. Heart J. 26, 215–225 (2005).
   PubMed Web of Science ®Google Scholar
• Shah RV, Desai AS, Givertz MM. The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis. J. Card. Fail. 16(3), 260–267 (2010).
   PubMed Web of Science ®Google Scholar
• Meune C, Wahbi K, Duboc D, Weber SJ. Meta-analysis of Renin-Angiotensin-aldosterone blockade for heart failure in presence of preserved left ventricular function. Cardiovasc. Pharmacol. Ther. 16(3–4), 368–375 (2011).
   PubMed Web of Science ®Google Scholar
• Givertz MM, Colucci WS, Blockers B. Atlas of Heart Failure Book (5th edition). Colucci WS (Ed.). Springer science+Business Media Publisher, 165–184 (2008).
   Google Scholar
• Adrian F Hernandez, Bradley G Hammill, Christopher M O’Connor. Clinical effectiveness of beta-blockers in heart failure findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) registry. JACC 53(2), 184–192 (2009).
   Google Scholar
• Ignarro LJ. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third generation b-blocker. Blood Press Suppl. 13(1), 2–16 (2004).
   Google Scholar
• Zanchetti A. Clinical pharmacodynamics of nebivolol: new evidence of nitric-oxide mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients. Blood Press. 13, 18–33 (2004).
   Web of Science ®Google Scholar
• Kuroedov A, Cosentino F, Luscher TF. Pharmacological mechanisms of clinically favorable properties of a selective beta1-adrenoceptor antagonist. Nebivolol. Cardiovasc. Drug Rev. 22, 155–168 (2004).
   PubMed Web of Science ®Google Scholar
• Conraads VM, Metra M, Kamp O et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur. J. Heart Fail. 14, 219–225 (2012).
   PubMed Web of Science ®Google Scholar
• Edelmann F, Gelbrich G, Düngen H-D et al. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. JACC 58 (17), 1780–1791 (2011).
   Google Scholar
• Edelmann F, Wachter R, Schmidt AG et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction the Aldo-DHF randomized controlled trial. JAMA 309 (8), 781–791 (2013).
   PubMed Web of Science ®Google Scholar
• Redfield MM, Chen HH, Borlaug BA, Semigran MJ. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 309(2), 1268–1277 (2013).
   PubMed Web of Science ®Google Scholar
• Park JH, Marwick TH. Use and limitations of E/E′ to assess left ventricular filling pressure by echocardiography. J. Cardiovasc. Ultrasound. 19 (4), 169–173 (2011).
   PubMedGoogle Scholar